Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
Crossref DOI link: https://doi.org/10.1038/s41575-024-00904-5
Published Online: 2024-02-12
Published Print: 2024-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hindson, Jordan
Text and Data Mining valid from 2024-02-12
Version of Record valid from 2024-02-12
Article History
First Online: 12 February 2024